卫光生物(002880) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥168,889,078.86, representing a 28.88% increase compared to ¥131,048,503.56 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2019 was ¥26,979,739.00, up 9.04% from ¥24,743,545.96 in the previous year[8]. - Basic and diluted earnings per share increased to ¥0.25, an 8.70% rise from ¥0.23 in the previous year[8]. - Total operating revenue for Q1 2019 reached ¥168,889,078.86, an increase of 28.9% compared to ¥131,048,503.56 in the same period last year[55]. - Net profit for Q1 2019 was ¥26,979,739.00, representing a growth of 9.0% from ¥24,743,545.96 in Q1 2018[57]. - The total comprehensive income for the current period is ¥26,979,739.00, compared to ¥24,743,545.96 in the previous period, indicating an increase of 9.0%[62]. Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥15,508,316.50, a 66.86% reduction from a net outflow of ¥46,795,670.89 in the same period last year[8]. - Cash received from sales of goods and services increased by 45.8% year-on-year, attributed to higher product sales volume[18]. - Cash flow from operating activities shows a net outflow of ¥15,508,316.50, an improvement from a net outflow of ¥46,795,670.89 in the previous period[73]. - The cash inflow from operating activities totaled ¥156,872,653.45, compared to ¥108,172,146.80 in the previous period, reflecting a growth of 45.0%[73]. - The net increase in cash and cash equivalents was -CNY 63,166,722.01, compared to -CNY 51,442,049.55 in the previous period[82]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,432,109,270.04, a decrease of 1.86% from ¥1,459,319,731.47 at the end of the previous year[8]. - The company's current assets totaled approximately CNY 895.89 million, down from CNY 925.06 million at the end of 2018, indicating a decrease of about 3.2%[35]. - Total liabilities decreased to approximately CNY 99.34 million from CNY 153.53 million, a significant reduction of about 35.2%[41]. - The company's equity attributable to shareholders increased to approximately CNY 1.33 billion from CNY 1.31 billion, marking a growth of about 3.8%[44]. - The company's cash and cash equivalents decreased to approximately CNY 207.41 million from CNY 260.32 million, a decline of about 20.2%[35]. Operating Costs and Expenses - Operating costs increased by 41.83% year-on-year, primarily due to an increase in product sales volume[18]. - Total operating costs for Q1 2019 were ¥138,221,768.80, up 33.1% from ¥103,776,809.01 in Q1 2018[55]. - Research and development expenses increased by 110.45% year-on-year, mainly due to increased investment in fibrinogen and rabies vaccine projects[18]. - Research and development expenses increased significantly to ¥10,619,924.17, compared to ¥5,046,400.70 in the previous period, reflecting a growth of 110.4%[63]. - Income tax expenses increased by 30.41% year-on-year, mainly due to an increase in total profit leading to higher tax provisions[18]. Shareholder Information - The top shareholder, Shenzhen Guangming Group, holds 65.25% of the shares, with a total of 70,470,000 shares[12]. - The net assets attributable to shareholders increased by 2.07% to ¥1,332,764,501.05 from ¥1,305,784,762.05 at the end of the previous year[8]. Other Information - The company received government subsidies amounting to ¥1,880,811.27 during the reporting period[8]. - There were no significant changes in the company's strategy or new product developments mentioned during the call[17]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[30]. - The company did not undergo an audit for the first quarter report[83].